Log In
Print
BCIQ
Print
Print this Print this
 

Kazano, Vipdomet, alogliptin/metformin

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionFixed-dose combination of alogliptin plus metformin
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of ActionDipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes; Treat Type II diabetics who are uncontrolled on existing therapies
Regulatory Designation

Partner

Actavis plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today